Keyword: Herceptin

With biosim rivals looming, Roche will need its newer meds to step up, and Wednesday's Kadcyla data could give its breast cancer franchise a boost.

Genentech filed a lawsuit against former employees accused of stealing trade secrets, calling on a court to issue an injunction and award damages.

The Herceptin sales decline is a preview of how biosimilar competition could impact the top lines of Roche and other innovators, Bernstein says.

Roche’s blockbuster cancer trio held their ground so far this year despite biosimilar rivals in the EU, thanks to growth in the U.S. and China.

Roche is teeing up a new use for its breast cancer drug Kadcyla, hoping to gin up sales as Herceptin biosimilars hurtle toward the U.S. market.

An independent panel of FDA advisers endorsed Celltrion’s Rituxan biosimilar, sending the program to the FDA for a final say.

Here is some other vaccine news of note for the week.

Ahead of an FDA panel meeting for Celltrion's Rituxan biosimilar, agency reviewers noted "clinically meaningful differences" between the products.

A Takeda founder descendant blasts the Shire deal, as the company moves its U.S. HQ closer to Shire; Sanofi revamps two global units.